Avid Bioservices (CDMO) Misses Q2 EPS by 2c, Revenue Beats

Avid Bioservices (NASDAQ: CDMO) reported Q2 EPS of $0.02, $0.02 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $36.7 million versus the consensus estimate of $33.44 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Lumentum shares rise on analyst upgrades, AI demand outlook
• Amneal gets FDA approval for lanreotide injection, launches immediately